| scholarly article | Q13442814 |
| P2093 | author name string | R M Elashoff | |
| D L Morton | |||
| J A Nizze | |||
| J H Wong | |||
| L Wanek | |||
| P2860 | cites work | Current management of malignant melanoma | Q68864784 |
| Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site | Q69463555 | ||
| Suppressor cell activity in melanoma-draining lymph nodes | Q70023437 | ||
| Prognosis of patients with pathologic stage II cutaneous malignant melanoma | Q70048010 | ||
| Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities | Q70332864 | ||
| Results of ilioinguinal dissection for stage II melanoma | Q70391886 | ||
| A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II) | Q70717837 | ||
| Altered lymphatic drainage following lymphadenectomy | Q71235425 | ||
| Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma | Q24540048 | ||
| The role of elective lymph node dissection in melanoma: rationale, results, and controversies | Q39625646 | ||
| Comparison of the classification by microscopic level (stage) of malignant melanoma by three independent groups of pathologists | Q40069544 | ||
| Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma | Q40231251 | ||
| Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases | Q40540112 | ||
| Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes | Q41457969 | ||
| Tumor-associated antigen immune complexes. A potential marker of recurrent melanoma | Q43866555 | ||
| Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. | Q46012249 | ||
| Histomorphometry in the assessment of prognosis in stage II malignant melanoma | Q46104103 | ||
| Demonstration in sarcoma patients of anti-tumor antibodies which fix only human complement | Q47672542 | ||
| Inefficacy of immediate node dissection in stage 1 melanoma of the limbs | Q50986397 | ||
| Malignant melanoma prognostic factors 7: elective lymph node dissection. | Q52871928 | ||
| Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning | Q67237614 | ||
| A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma.Preliminary results | Q67316111 | ||
| The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: a preliminary study | Q67412153 | ||
| Malignant melanoma of the head and neck | Q67459536 | ||
| A rational approach to the surgical management of melanoma | Q67683651 | ||
| BCG immunotherapy of malignant melanoma: summary of a seven-year experience | Q68788101 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| lymphadenectomy | Q1809305 | ||
| P304 | page(s) | 491-9; discussion 499-501 | |
| P577 | publication date | 1991-10-01 | |
| P1433 | published in | Annals of Surgery | Q4767866 |
| P1476 | title | Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic | |
| P478 | volume | 214 |
| Q49015294 | A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up |
| Q24654139 | A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire |
| Q52142486 | A historical perspective on the development of intraoperative lymphatic mapping and selective lymphadenectomy. |
| Q36201336 | A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma |
| Q44869575 | A new American Joint Committee on Cancer staging system for cutaneous melanoma |
| Q30931923 | A note from history: Landmarks in history of cancer, part 7. |
| Q92817308 | Adequacy of sentinel lymph node biopsy in malignant melanoma of the trunk and extremities: Clinical observations regarding prognosis |
| Q73728291 | Adjuvant therapy of malignant melanoma |
| Q50524264 | Advances in melanoma therapy. |
| Q38030894 | Analysis of regional recurrence after negative sentinel lymph node biopsy for head and neck melanoma |
| Q44128741 | Another brick in the wall: toward a better understanding of melanoma of unknown primary |
| Q34209883 | Basal cell carcinoma over chest wall (Sternum) treated with dufourmentel flap: Report of a case with review of literature |
| Q89017223 | Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma? |
| Q77366769 | Classification and staging of melanoma |
| Q36165408 | Clinical and biological aspects of sentinel node biopsy in malignant melanoma--an update |
| Q26747723 | Clinical utilities and biological characteristics of melanoma sentinel lymph nodes |
| Q33776993 | Critical review of the sentinel node hypothesis |
| Q35652997 | Current management of the axilla in patients with clinically node-negative breast cancer: a nationwide survey of United Kingdom breast surgeons |
| Q36668237 | Current surgical management of melanoma |
| Q50456824 | Dermoscopy structures as predictors of sentinel lymph node positivity in cutaneous melanoma. |
| Q52767151 | Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. |
| Q44714604 | Diversity of stage III melanoma in the era of sentinel lymph node biopsy |
| Q36715613 | Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patients with melanoma |
| Q46844304 | EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. |
| Q56828355 | EORTC Melanoma Group achievements |
| Q46136921 | Effective low-dose escalation of indocyanine green for near-infrared fluorescent sentinel lymph node mapping in melanoma |
| Q40717524 | Elective lymph node dissection for melanoma |
| Q40520492 | Epidemiology, management and survival outcomes of primary cutaneous melanoma: a ten-year overview |
| Q85043057 | Evolving treatment strategies in thin cutaneous head and neck melanoma: 1 institution's experience |
| Q33954883 | Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients |
| Q45201798 | Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression |
| Q40987316 | Favorable prognostic factors in recurrent and metastatic melanoma |
| Q33760173 | Final trial report of sentinel-node biopsy versus nodal observation in melanoma |
| Q34093600 | Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients |
| Q46022389 | Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. |
| Q37301008 | Immunotherapy for advanced melanoma. |
| Q35126556 | Immunotherapy of malignant melanoma |
| Q37307652 | Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories |
| Q57741285 | Impact of sentinel lymphadenectomy on survival in a murine model of melanoma |
| Q37618735 | Impact of the false-negative sentinel lymph node biopsy in melanoma |
| Q37832409 | Implementing sentinel lymph node biopsy programs in developing countries: challenges and opportunities |
| Q50222966 | Indocyanine green and fluorescence lymphangiography for sentinel lymph node identification in cutaneous melanoma |
| Q36421679 | Intraoperative identification of sentinel lymph node in patients with malignant melanoma |
| Q74012235 | Judging the therapeutic value of lymph node dissections for melanoma |
| Q34659721 | Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis |
| Q37370769 | Lymph node ratio predicts disease-specific survival in melanoma patients |
| Q33726162 | Lymphatic mapping and sentinel lymphadenectomy after wide local excision of primary melanoma |
| Q47581057 | Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases |
| Q36532123 | Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma |
| Q46125923 | Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma |
| Q58690762 | Malignant melanoma |
| Q73643261 | Malignant melanoma |
| Q35084330 | Malignant melanoma: current state of primary and adjuvant treatment |
| Q40709215 | Management of Conjunctival Melanoma: Critical Assessment of Sentinel Lymph Node Biopsy |
| Q34436502 | Management of high-risk melanoma |
| Q42106687 | Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells |
| Q50540269 | Metastatic Melanoma in Sentinel Node-Negative Patients: The Ottawa Experience. |
| Q34446657 | Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site. |
| Q34315676 | Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases |
| Q37919776 | Pathways for cervical metastasis in malignant neoplasms of the head and neck region |
| Q48831498 | Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology |
| Q74784641 | Preservation of muscle fascia to decrease lymphedema after complete axillary and ilioinguinofemoral lymphadenectomy for melanoma |
| Q41713870 | Principles and guidelines for surgeons: management of cutaneous malignant melanoma. European Society of Surgical Oncology Brussels |
| Q43853642 | Prognostic Significance of Reverse Transcriptase-Polymerase Chain Reaction?Negative Sentinel Nodes in Malignant Melanoma |
| Q43786951 | Prognostic evaluation of cutaneous malignant melanoma based on the pTNM classification |
| Q34964449 | Prognostic factors |
| Q33797051 | Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients |
| Q78341872 | Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes |
| Q35545019 | Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma |
| Q38200004 | Recent developments in the medical and surgical treatment of melanoma |
| Q71873324 | Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax |
| Q74552332 | Role of elective lymph node dissection in melanoma |
| Q87573784 | Role of sentinel lymph node biopsy in patients with Merkel cell carcinoma: statistical analysis of 403 reported cases |
| Q50057700 | SPECT/CT Adds Distinct Lymph Node Basins and Influences Radiologic Findings and Surgical Approach for Sentinel Lymph Node Biopsy in Head and Neck Melanoma. |
| Q38190113 | Sentinel lymph node biopsy in melanoma: controversies and current guidelines |
| Q51802303 | Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. |
| Q52040414 | Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. |
| Q33890196 | Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute |
| Q74063658 | Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma |
| Q82674494 | Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? |
| Q36648843 | Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors |
| Q34964496 | Surgical approaches to malignant melanoma. Practical guidelines |
| Q40467029 | Surgical management of regional lymph nodes in primary cutaneous malignant melanoma |
| Q35105675 | Surgical treatment of malignant melanoma |
| Q58028886 | Testing a new staging system for cutaneous melanoma proposed by the American Joint Committee on Cancer |
| Q73615764 | The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group |
| Q34611113 | The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma |
| Q39860307 | The competent sentinel node: an association with an axillary presentation and an occult or a small primary invasive breast carcinoma |
| Q33828582 | The concept of sentinel node localization: how it started |
| Q45907797 | The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients. |
| Q39317681 | The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients. |
| Q34584396 | The role of sentinel lymph node biopsy in the management of melanoma |
| Q45102326 | Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma |
| Q88984062 | Unusual presentation of primary cutaneous melanoma of the forearm with epitrochlear and axillary lymphadenopathy |
| Q41589321 | Update on active specific immunotherapy with melanoma vaccines |
| Q37920834 | Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate |
| Q33752235 | Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group |
| Q77376752 | Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma |
Search more.